
The #NIMBUS trial results are now published in @NatureComms 👉Nivolumab plus low-dose #ipilimumab in hypermutated HER2-negative #MetastaticBreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/40360544/ ✍️@jgtzanudo @smreddymd @EmensLeisha @CarolinaAlvesC5 @s_aldubayan @hoyin_chu @nlinmd @NabihahTayob @RMJesel @EMittendorfMD @stolaney1





























